The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
A Meta-analysis Comparing the Effect of Thiazolidinediones on Cardiovascular Risk Factors
Abstract
BACKGROUND: In patients with type 2 diabetes mellitus, all therapeutic options should be evaluated for their effect on cardiovascular risk factors, in addition to glycemic control. We conducted a meta-analysis of randomized controlled trials of pioglitazone hydrochloride and rosiglitazone maleate in patients with type 2 diabetes to evaluate their effect on glycemic control, lipids, blood pressure, and weight. METHODS: Randomized controlled trials of patients with type 2 diabetes that compared pioglitazone or rosiglitazone with placebo for 12 weeks were included. Primary analysis was to compare thiazolidinediones with placebo. Secondary analysis was to identify whether treatment with pioglitazone differed from rosiglitazone in any outcomes. We calculated weighted mean differences and 95% confidence intervals. RESULTS: Twenty-three randomized controlled trials were identified. Both thiazolidinediones demonstrated similar hemoglobin A(1c) level decreases of 1.0% to 1.5% and similar increases in body weight of approximately 3.0 kg. Pioglitazone significantly lowered triglyceride level (-40 mg/dL [-0.45 mmol/L]; 95% confidence interval [CI], -53 to -26 mg/dL [-0.60 to -0.29 mmol/L]), increased high-density lipoprotein cholesterol (HDL-C) level (+4.6 mg/dL [+0.12 mmol/L]; 95% CI, 3.6 to 5.5 mg/dL [0.09 to 0.14 mmol/L]), and showed neutral effect on low-density lipoprotein cholesterol (LDL-C) and total cholesterol levels. Rosiglitazone significantly increased HDL-C level (+2.7 mg/dL [+0.07 mmol/L]; 95% CI, 2.0 to 3.4 mg/dL [0.05 to 0.09 mmol/L]), but increased LDL-C level (+15 mg/dL [+0.39 mmol/L]; 95% CI, 13 to 17 mg/dL [0.34 to 0.44 mmol/L]), total cholesterol level (+21 mg/dL [+0.54 mmol/L]; 95% CI, 18 to 25 mg/dL [0.47 to 0.65 mmol/L]), and demonstrated neutral effect on triglyceride level (-1.1 mg/dL [-0.12 mmol/L]; 95% CI, -14 to 12 mg/dL [-0.16 to 0.14 mmol/L]). No data were available on pioglitazone and blood pressure. Rosiglitazone had a neutral effect on systolic (-0.7 mm Hg; 95% CI, -2.6 to 1.1 mm Hg) and diastolic (-0.8 mm Hg; 95% CI, -1.8 to 0.3) blood pressure. CONCLUSIONS: Thiazolidinediones have similar effects on glycemic control and body weight. Pioglitazone produced a more favorable lipid profile. Head-to-head comparative trials as well as longer-term cardiovascular outcome studies are needed to determine whether there are differences in efficacy between the 2 thiazolidinediones.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001
Mokdad, A. H., Ford, E. S., Bowman, B. A., Dietz, W. H., Vinicor, F., Bales, V. S., & Marks, J. S. (2003) · JAMA · doi:10.1001/jama.289.1.76 · Cited by 5,866
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
Lakka, H.-M. (2002) · JAMA · doi:10.1001/jama.288.21.2709 · Cited by 5,033
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760
DeFronzo, R. A., & Ferrannini, E. (1991) · Diabetes Care · doi:10.2337/diacare.14.3.173 · Cited by 4,535
Self-citationHubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
The Continuing Epidemics of Obesity and Diabetes in the United States
Mokdad, A. H. (2001) · JAMA · doi:10.1001/jama.286.10.1195 · Cited by 2,730
Alexander, C. M., Landsman, P. B., Teutsch, S. M., & Haffner, S. M. (2003) · Diabetes · doi:10.2337/diabetes.52.5.1210 · Cited by 1,475
A Prospective Study of Obesity and Risk of Coronary Heart Disease in Women
Manson, J. E., Colditz, G. A., Stampfer, M. J., Willett, W. C., Rosner, B., Monson, R. R., Speizer, F. E., & Hennekens, C. H. (1990) · New England Journal of Medicine · doi:10.1056/nejm199003293221303 · Cited by 1,408
Diabetes and Glucose Tolerance as Risk Factors for Cardiovascular Disease: The Framingham Study
Kannel, W. B., & McGee, D. L. (1979) · Diabetes Care · doi:10.2337/diacare.2.2.120 · Cited by 1,203 · cited 1×
“syndrome, with or without type 2 diabetes, are at increased risk of CVD.(40-43)”
Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971–1993
Gu, K., Cowie, C. C., & Harris, M. I. (1998) · Diabetes Care · doi:10.2337/diacare.21.7.1138 · Cited by 881 · cited 2×
“200000 deaths a year, primarily from cardiovascular disease (CVD).(2) Strategies that”
Miyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8567 · Cited by 726
Bays, H., Mandarino, L., & DeFronzo, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030723 · Cited by 664
Self-citationAronoff, S., Rosenblatt, S., Braithwaite, S., Egan, J. W., Mathisen, A. L., & Schneider, R. L. (2000) · Diabetes Care · doi:10.2337/diacare.23.11.1605 · Cited by 629
Fonseca, V., Rosenstock, J., Patwardhan, R., & Salzman, A. (2000) · JAMA · doi:10.1001/jama.283.13.1695 · Cited by 540
Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes
Lebovitz, H. E., Dole, J., Patwardhan, R., Rappaport, E. B., & Freed, M. I. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.1.280 · Cited by 518
Stern, M. P., Williams, K., & Haffner, S. M. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-8-200204160-00006 · Cited by 510
Miyazaki, Y., Mahankali, A., Matsuda, M., Glass, L., Mahankali, S., Ferrannini, E., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.710 · Cited by 407
Self-citationEinhorn, D., Rendell, M., Rosenzweig, J., Egan, J. W., Mathisen, A. L., & Schneider, R. L. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)83039-8 · Cited by 368
Koshiyama, H. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.7.3452 · Cited by 362
Raskin, P., Rendell, M., Riddle, M. C., Dole, J. F., Freed, M. I., Rosenstock, J., & For the Rosiglitazone Clinical Trials Study Group (2001) · Diabetes Care · doi:10.2337/diacare.24.7.1226 · Cited by 345
Phillips, L. S., Grunberger, G., Miller, E., Patwardhan, R., Rappaport, E. B., Salzman, A., & the Rosiglitazone Clinical Trials Study Group (2001) · Diabetes Care · doi:10.2337/diacare.24.2.308 · Cited by 302
Satoh, N., Ogawa, Y., Usui, T., Tagami, T., Kono, S., Uesugi, H., Sugiyama, H., Sugawara, A., Yamada, K., Shimatsu, A., et al. (2003) · Diabetes Care · doi:10.2337/diacare.26.9.2493 · Cited by 289
Kipnes, M. S., Krosnick, A., Rendell, M. S., Egan, J. W., Mathisen, A. L., & Schneider, R. L. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00713-6 · Cited by 281
Miyazaki, Y., Glass, L., Triplitt, C., Matsuda, M., Cusi, K., Mahankali, A., Mahankali, S., Mandarino, L. J., & DeFronzo, R. A. (2001) · Diabetologia · doi:10.1007/s001250100031 · Cited by 274
Self-citationA Diabetes Outcome Progression Trial (ADOPT)
Viberti, G., Kahn, S. E., Greene, D. A., Herman, W. H., Zinman, B., Holman, R. R., Haffner, S. M., Levy, D., Lachin, J. M., Berry, R. A., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.10.1737 · Cited by 273
Wolffenbuttel, B. H. R., Gomis, R., Squatrito, S., Jones, N. P., & Patwardhan, R. N. (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00224.x · Cited by 264
Rosenblatt, S., Miskin, B., Glazer, N. B., Prince, M. J., & Robertson, K. E. (2001) · Coronary Artery Disease · doi:10.1097/00019501-200108000-00011 · Cited by 221
Zavaroni, I., Bonini, L., Gasparini, P., Barilli, A. L., Zuccarelli, A., Dall'Aglio, E., Delsignore, R., & Reaven, G. M. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90195-6 · Cited by 206
Rosenstock, J., Einhorn, D., Hershon, K., Glazer, N., & Yu, S. (2002) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2002.tb11251.x · Cited by 193
Takagi, T., Akasaka, T., Yamamuro, A., Honda, Y., Hozumi, T., Morioka, S., & Yoshida, K. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00895-0 · Cited by 187
Patel, J., Anderson, R. J., & Rappaport, E. B. (1999) · Diabetes, Obesity and Metabolism · doi:10.1046/j.1463-1326.1999.00020.x · Cited by 181
Chilcott, J. B., Tappenden, P., Jones, M. L., & Wight, J. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)80078-8 · Cited by 162
Assessment of Excess Mortality in Obesity
Bender, R., Trautner, C., Spraul, M., & Berger, M. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009365 · Cited by 155
Takagi, T., Yamamuro, A., Tamita, K., Yamabe, K., Katayama, M., Mizoguchi, S., Ibuki, M., Tani, T., Tanabe, K., Nagai, K., et al. (2003) · American Heart Journal · doi:10.1016/s0002-8703(03)00146-7 · Cited by 154
Dorn, J. M., Schisterman, E. F., Winkelstein, W., & Trevisan, M. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009218 · Cited by 142
Herz, M., Johns, D., Reviriego, J., Grossman, L. D., Godin, C., Durán, S., Hawkins, F. G., Lochnan, H. A., Escobar‐Jiménez, F., Hardin, P. A., et al. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80068-1 · Cited by 132
Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes
Gomez-Perez, F. J., Fanghänel‐Salmón, G., Barbosa, J. A., Montes‐Villarreal, J., Berry, R. A., Warsi, G. M., & Gould, E. M. (2002) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.264 · Cited by 113
Plutzky, J. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00614-3 · Cited by 82
Scherbaum, W. A., Göke, B., & and the German Pioglitazone Study Group (2002) · Hormone and Metabolic Research · doi:10.1055/s-2002-35421 · Cited by 80
Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes
Osman, A., Otero, J., Brizolara, A. A., Waxman, S., Stouffer, G. A., Fitzgerald, P. J., & Uretsky, B. F. (2004) · American Heart Journal · doi:10.1016/j.ahj.2003.12.006 · Cited by 71
Vongthavaravat, V., WAJCHENBERG, B. L., Waitman, J. N., Añel-Quimpo, J., Menon, P. S. N., Khalifa, F. B., & Chow, W.-H. (2002) · Current Medical Research and Opinion · doi:10.1185/030079902125001236 · Cited by 40
Wurch, T., Junquero, D. C., Delhon, A., & Pauwels, P. J. (2002) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-001-0504-z · Cited by 34
Rosiglitazone in Type 2 diabetes mellitus: an evaluation in British Indo‐Asian patients
Barnett, A. H., Grant, P. J., Hitman, G. A., Mather, H. M., Pawa, M., Robertson, L., & Trelfa, A. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.00925.x · Cited by 29
The clinical effectiveness and cost effectiveness of rosiglitazone for type 2 diabetes mellitus
Lord, J. L., Paisley, S., & Taylor, R. (2000) · Brunel University Research Archive (BURA) (Brunel University London) · Cited by 7
Cited by
Creely, S. J., McTernan, P. G., Kusminski, C. M., Fisher, F. M., Da Silva, N. F., Khanolkar, M., Evans, M., Harte, A. L., & Kumar, S. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00302.2006 · Cited by 1,043
DeFronzo, R. A. (2010) · Diabetologia · doi:10.1007/s00125-010-1684-1 · Cited by 879
Self-citationBolen, S., Feldman, L., Vassy, J., Wilson, L., Yeh, H.-C., Marinopoulos, S., Wiley, C., Selvin, E., Wilson, R., Bass, E. B., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-6-200709180-00178 · Cited by 823
Goldberg, R. B., Kendall, D. M., Deeg, M. A., Buse, J. B., Zagar, A. J., Pinaire, J. A., Tan, M. H., Khan, M. A., Perez, A. T., Jacober, S. J., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1547 · Cited by 795
Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
Di Pino, A., & DeFronzo, R. A. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00141 · Cited by 535
Self-citation
Metadata
- Authors
- Chiquette, E., Ramirez, G., & DeFronzo, R.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2004-10-25
- Volume
- 164
- Issue
- 19
- Pages
- 2097
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W1982990554
- Cited by
- 291
- References
- 48
- FWCI
- 19.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.